Body System
Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market
Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures
RayzeBio Warned of Potential Actinium Isotope Supply Issues Before $4.1B BMS Deal
RayzeBio, Bristol Myers Squibb, Actinium-225, Isotope Supply Issues, Radiopharmaceuticals, Neuroendocrine Tumors
Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease
** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment
Semaglutide Significantly Improves Cardiovascular Health and Reduces Mortality Risk in Kidney Disease Patients, Novo Reports
Semaglutide, Novo, cardiovascular health, kidney disease, mortality risk, clinical trial
Beyond Weight Loss: Wegovy’s Cardiovascular Benefits Uncovered in New Study
Wegovy, cardiovascular benefits, weight loss, GLP-1 receptor agonist, heart health, obesity treatment, diabetes management, clinical study.
Incyte Expands Portfolio with $750 Million Acquisition of Escient, a Pioneer in Immune and Neuro Biotechnology
Incyte, Escient, biotechnology, immune system, neuroscience, acquisition, deal, $750 million, portfolio expansion, drug development, therapeutics, GPCR targets.
Novo Nordisk’s Ozempic Shows Promising Kidney Benefits for Diabetic Patients
Ozempic, Novo Nordisk, Chronic kidney disease, Cardiovascular events, Expanded use, Semaglutide, FLOW trial, Reduced risk, Type 2 diabetes